Dr. Jun Zhu: Advancing Lymphoma Drug Development in China to Propel the Discipline and Hospital Growth

Dr. Jun Zhu: Advancing Lymphoma Drug Development in China to Propel the Discipline and Hospital Growth

2024.09.11
Under the leadership of Dr. Jun Zhu, the Lymphoma Department at Peking Cancer Hospital has become a frontrunner in lymphoma drug development. This year, what innovative achievements from the team will illuminate the treatment path for lymphoma patients? How have they showcased Chinese expertise on the international stage? Additionally, how will the opportunities and challenges China faces in new drug development be transformed into driving forces to enhance lymphoma treatment standards? At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the honor of conducting an in-depth interview with Dr. Jun Zhu. During the discussion, Professor Zhu not only reviewed the illustrious journey of China's lymphoma drug development but also, with his profound insights and forward-looking perspective, envisioned the limitless possibilities in this field's future. Let us delve into Professor Zhu’s remarkable analysis and unique insights on the development of lymphoma drugs in China.
Dr. Guohong Han’s Team: Measuring Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

Dr. Guohong Han’s Team: Measuring Portal Pressure Gradient 24 Hours Post-TIPS Provides More Accurate Risk Prediction for Complications

2024.09.11
Portal hypertension is a severe complication of chronic liver disease, directly associated with clinical outcomes such as ascites and variceal bleeding. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective treatment that significantly reduces portal pressure. Portal pressure gradient (PPG) is commonly used to assess portal pressure in patients undergoing TIPS. Recently, a study conducted by Dr. Guohong Han's team from Xi'an International Medical Center Hospital that published in the Journal of Hepatology, explored the optimal timing of measurement and hemodynamic target of PPG in cirrhotic patients with variceal bleeding undergoing covered stent TIPS. Dr. Yong Lv from Xijing Hospital is the first author of this article, and Dr. Guohong Han is the corresponding author.
WCLC Expert Commentary: Dr. Nan Bi Discusses the LAURA Study Results and the Challenges of EGFR-Positive LA-NSCLC Targeted Consolidation Therapy

WCLC Expert Commentary: Dr. Nan Bi Discusses the LAURA Study Results and the Challenges of EGFR-Positive LA-NSCLC Targeted Consolidation Therapy

2024.09.11
The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently underway in San Diego, USA. Oncology Frontier has invited leading Chinese lung cancer experts to analyze the key research data from this conference. This article highlights Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, as she shares her thoughts on the LAURA study results (Abstract No. OA12.03).
WCLC China Special Session: Exploring Global Lung Cancer Prevention and Evidence-Based Medicine

WCLC China Special Session: Exploring Global Lung Cancer Prevention and Evidence-Based Medicine

2024.09.11
At the 2024 World Conference on Lung Cancer (WCLC), the International Association for the Study of Lung Cancer (IASLC), the Chinese Society of Clinical Oncology (CSCO), and the Chinese Alliance Against Lung Cancer (CAALC) came together once again to host a joint session. Held on Saturday, September 7, from 8:00 AM to 12:00 PM, the session focused on the development and future prospects of evidence-based medicine in lung cancer prevention worldwide. The session was chaired by IASLC President-Elect, Dr. Caizun Zhou from Shanghai East Hospital, alongside Dr. Yilong Wu from Guangdong Provincial People's Hospital, IASLC CEO Dr. Karen Kelly, and Dr. Chunxue Bai from Fudan University’s Zhongshan Hospital.
Dr.Yuankai Shi: INTELLECT Study Reveals mOS of 41.8 Months, Offering Prolonged Survival for NSCLC Patients Resistant to Crizotinib

Dr.Yuankai Shi: INTELLECT Study Reveals mOS of 41.8 Months, Offering Prolonged Survival for NSCLC Patients Resistant to Crizotinib

2024.09.11
The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) was held in San Diego, CA USA on September 7th. The mOS data from the INTELLECT study was disclosed at the conference on September 8th. Oncology Frontier has invited the lead principal investigator of the INTELLECT study, Dr. Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences, to share the latest findings from this groundbreaking research reported at the WCLC. This study highlights the promising outcomes of Iruplinakib treatment for advanced NSCLC patients resistant to crizotinib.
WCLC 2024 | Dr. Patel Discusses the Anticipation for IASLC’s 50th Anniversary Celebration

WCLC 2024 | Dr. Patel Discusses the Anticipation for IASLC’s 50th Anniversary Celebration

2024.09.10
The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). This milestone celebration will feature unique activities commemorating IASLC’s rich history, under the theme "Across the Decades." The event will be held on September 8 in San Diego’s famous Gaslamp Quarter, where attendees can enjoy local cuisine, dance, and commemorative attire throughout the evening.
Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

2024.09.10
Recently, Professor Xiaofan Zhu, Director of the Division of Pediatric Hematology and Oncology Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Associate Chief Physician Doctor Min Ruan and Attending Doctor LiPeng Liu collaborated on a study titled "Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA," published in Clinical Cancer Research (with an impact factor of 11.5). This prospective study was the first to evaluate the longitudinal changes of ctDNA from plasma in patients, as compared to NGS based bone marrow DNA, for the early detection of relapse in children with AML.